Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus NUZYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus NUZYRA.
AUREOMYCIN vs NUZYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Omadacycline is a aminomethylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
200 mg intravenously once on day 1, then 100 mg IV once daily; or 200 mg orally once on day 1, then 100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Terminal elimination half-life is approximately 17-21 hours; supports once-daily dosing.
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Fecal (approximately 76%) as unchanged drug; renal (approximately 14%) as unchanged drug; biliary excretion is minimal.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic